Phosphate restriction significantly reduces mortality in uremic rats with established vascular calcification

Kidney International

Volumn 84, Issue 6, 2013, Pages 1145-1153

  Finch, Jane L ^a   Lee, Duk H ^b   Liapis, Helen ^a   Ritter, Cindy ^a   Zhang, Sarah ^a   Suarez, Edu ^c   Ferder, Leon ^c   Slatopolsky, Eduardo ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Daegu Fatima Hospital   (South Korea)

^c PONCE SCHOOL OF MEDICINE   (Puerto Rico)

Author keywords

FGF 23; mortality; phosphate; PTH; renal failure; vascular calcification

Indexed keywords

CALCIUM PHOSPHATE; OSTEOPONTIN; PHOSPHATE; TRANSCRIPTION FACTOR RUNX2;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL INFILTRATION; CONTROLLED STUDY; CORONARY ARTERY CALCIFICATION; DIET RESTRICTION; DISEASE SEVERITY; FEMALE; GLOMERULOSCLEROSIS; HEART MUSCLE CELL; KIDNEY INJURY; MACROPHAGE; MORTALITY; NONHUMAN; PHOSPHATE BLOOD LEVEL; PHOSPHATE INTAKE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; RISK REDUCTION; UPREGULATION; UREMIA; VASCULAR FIBROSIS;

ANIMALS; AORTA; BIOLOGICAL MARKERS; CALCIUM; CHELATING AGENTS; CORE BINDING FACTOR ALPHA 1 SUBUNIT; DIET; DISEASE MODELS, ANIMAL; FEMALE; FIBROBLAST GROWTH FACTORS; FIBROSIS; HYPERPHOSPHATEMIA; KIDNEY; MYOCARDIUM; OSTEOPONTIN; PARATHYROID HORMONE; PHOSPHATES; POLYAMINES; RATS; RATS, SPRAGUE-DAWLEY; TIME FACTORS; UREMIA; VASCULAR CALCIFICATION;

EID: 84888640276     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/ki.2013.213     Document Type: Article

References (51)

1. Foley RN, Parfrey PS, Sarnak MJ. Clinical epidemiology of cardiovascular disease in chronic renal disease. Am J Kidney Dis 1988; 32: S112-S119.
2. London GM, Guerin AP, Marchais SJ et al. Arterial media calcification in end stage renal disease: Impact on all cause and cardiovascular mortality. Nephrol Dial Transplant 2003; 18: 1731-1740.
3. Goodman WG, London G, Amman K et al. Vascular calcification in kidney disease. Am J Kidney Dis 2004; 43: 572-579.
4. Block GA, Hulbert-Shearon TE, Levin NW et al. Association of serum phosphorus and calcium-phosphate product with mortality risk in chronic hemodialysis patients: A national study. Am J Kidney Dis 1998; 31: 601-617.
5. Block GA, Port FK. Re-evaluation of risks associated with hyperphosphatemia and hyperparathyroidism in dialysis patients: Recommendations for a change in management. Am J Kidney Dis 2000; 35: 1226-1237.
6. Marco MP, Craver L, Betriu A et al. Higher impact of mineral metabolism on cardiovascular mortality in a European hemodialysis population. Kidney Int Suppl 2003; 85: S111-S114.
7. Noordzij M, Korevaar JC, Boeschoten EW et al. The Kidney Disease Outcomes Quality Initiative (K/DOQI) guideline for bone metabolism and disease in CKD: Association with mortality in dialysis patients. Am J Kidney Dis 2005; 46: 925-932.
8. Goldsmith DJ, Covic A, Sambrook PA et al. Vascular calcification in longterm haemodialysis patients in a single unit: A retrospective analysis. Nephron 1997; 77: 7-43.
9. Guerin AP, London GM, Marchais SJ et al. Arterial stiffening and vascular calcifications in end-stage renal disease. Nephrol Dial Transplant 2000; 15: 1014-1021.
10. Shanahan CM, Cary N, Salisbury JR et al. Medial localization of mineralization-regulating proteins in association with Mö nckeberg's sclerosis: Evidence for smooth muscle cell-mediated vascular calcification. Circulation 1999; 100: 2168-2176.
11. Shanahan CM, Cary NR, Metcalfe JC et al. High expression of genes for calcification-regulating proteins in human atherosclerotic plaques. J Clin Invest 1994; 93: 2393-2402.
12. Schoppet M, Al-Fakhri N, Franke FE et al. Localization of osteoprotegerin, tumor necrosis factor-related apoptosis-inducing ligand, and receptor activator of nuclear factor-kappaB ligand in Monckeberg's sclerosis and atherosclerosis. J Clin Endocrinol Metab 2004; 89: 4104-4112.
13. Levy RJ, Gundberg C, Scheinman R. The identification of the vitamin K-dependent bone protein osteocalcin as one of the gammacarboxyglutamic acid containing proteins present in calcified atherosclerotic plaque and mineralized heart valves. Atherosclerosis 1983; 46: 49-56.
14. Otto F, Thornell AP, Crompton T et al. Cbfa1, a candidate gene for cleidocranial dysplasia syndrome, is essential for osteoblast differentiation and bone development. Cell 1997; 89: 765-771.
15. Franceschi RT, Xiao G. Regulation of the osteoblast-specific transcription factor, Runx2: Responsiveness to multiple signal transduction pathways. J Cell Biochem 2003; 88: 446-454.
16. Giachelli CM, Speer MY, Li X et al. Regulation of vascular calcification: Roles of phosphate and osteopontin. Circ Res 2005; 96: 717-722.
17. Jono S, Peinado C, Giachelli CM. Phosphorylation of osteopontin is required for inhibition of vascular smooth muscle cell calcification. J Biol Chem 2000; 275: 20197-20203.
18. Steitz SA, Speer MY, Curinga G et al. Smooth muscle cell phenotypic transition associated with calcification: Up regulation of Cbfa 1 and down regulation of smooth muscle lineage markers. Circ Res 2001; 89: 1147-1154.
19. Panichi V, Bigazzi R, Paoletti S et al. Impact of calcium, phosphate, PTH abnormalities and management on mortality in hemodialysis: Results from the RISCAVID study. J Nephrol 2010; 23: 556-562.
20. Wilkes BM, Reiner D, Kern M et al. Simultaneous lowering of serum phosphate and LDL-cholesterol by sevelamer hydrochloride (Rena Gel) in dialysis patients. Clin Nephrol 1998; 50: 381-386.
21. Chertow GM, Burke SK, Raggi P. Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients. Kidney Int 2002; 62: 245-252.
22. Block GA, Spiegel DM, Erlich J et al. Effects of sevelamer and calcium on coronary artery calcification in patients new to hemodialysis. Kidney Int 2002; 68: 1815-1824.
23. Raggi P, Bommer J, Chertow GM. Valvular calcification in hemodialysis patients randomized to calcium-based phosphorus binders or sevelamer. J Heart Valve Dis 2004; 13: 134-141.
24. Ferramosca E, Burke S, Chasan-Taber S et al. Potential antiatherogenic and anti-inflammatory properties of sevelamer in maintenance hemodialysis patients. Am Heart J 2005; 149: 820-825.
25. Yamada K, Fujimoto S, Tokura T et al. Effect of sevelamer on dyslipidemia and chronic inflammation in maintenance hemodialysis patients. Ren Fail 2005; 27: 361-365.
26. Shantouf R, Budoff MJ, Ahmadi N et al. Effects of sevelamer and calciumbased phosphate binders on lipid and inflammatory markers in hemodialysis patients. Am J Nephrol 2008; 28: 275-279.
27. Caglar K, Yilmaz MI, Saglam M et al. Short-term treatment with sevelamer increases serum fetuin-A concentration and improves endothelial dysfunction in chronic kidney disease stage 4 patients. Clin J Am Soc Nephrol 2008; 3: 61-68.
28. Lopez I, Mendoza F, Guerrero F et al. The calcimimetic AMG 641 accelerates regression of extraosseous calcification in uremic rats. Am J Physiol Renal Physiol 2009; 296: F1376-F1385.
29. Adamczac M, Gross ML, Krtil J et al. Reversal of glomerulosclerosis after high-dose enalapril treatment in subtotally nephrectomized rats. J Am Soc Nephrol 2003; 14: 2833-2842.
30. Ortmann J, Amann K, Brandes RP et al. Role of podocytes for reversal of glomerulosclerosis and proteinuria in the aging kidney after endothelin inhibition. Hypertension 2004; 44: 974-981.
31. Ibels LS, Alfrey AC, Haut L et al. Preservation of function in experimental renal disease by dietary restriction of phosphate. N Engl J Med 1978; 298: 122-126.
32. Lau K. Phosphate excess and progressive renal failure: The precipitationcalcification hypothesis. Kidney Int 1989; 36: 918-937.
33. Loghmen-Adham M. Role of phosphate retention in the progression of renal failure. J Lab Clin Med 1993; 122: 15-25.
34. Cozzolino M, Staniforth ME, Liapis H et al. Sevelamer hydrochloride attenuates kidney and cardiovascular calcifications in long-term experimental uremia. Kidney Int 2003; 64: 1653-1661.
35. Nagano N, Miyata S, Obana S et al. Sevelamer hydrochloride, a phosphate binder, protects against deterioration of renal function in rats with progressive chronic renal insufficiency. Nephrol Dial Transplant 2003; 18: 2014-2023.
36. Kakuta T, Tanaka R, Hyodo T et al. Effect of sevelamer and calcium-based phosphate binders on coronary artery calcification and accumulation of circulating advanced glycation end products in hemodialysis patients. Am J Kidney Dis 2010; 57: 422-431.
37. Russo D, Miranda I, Ruocco C et al. The progression of coronary artery calcification in predialysis patients on calcium carbonate or sevelamer. Kidney Int 2007; 72: 1255-1261.
38. Chertow GM, Burke SK, Dillon MA et al. Long-term effects of sevelamer hydrochloride on the calcium-phosphate product and lipid profile of haemodialysis patients. Nephrol Dial Transplant 1999; 14: 2907-2914.
39. Vlassara H, Uribarri J, Weijing C et al. Effects of sevelamer on Hba1c, inflammation, and advanced glycation end products in diabetic kidney disease. Clin J Am Soc Nephrol 2012; 7: 934-942.
40. Zisman AL, Wolf M. Recent advances in the rapidly evolving field of fibroblast growth factor 23 in chronic kidney disease. Curr Opin Nephrol Hypertens 2010; 19: 335-342.
41. Desjardins L, Liabeuf S, Renard C et al. FGF23 is independently associated with vascular calcification but not bone mineral density in patients at various CKD stages. Osteoporos Int 2012; 23: 2017-2025.
42. Wolf M. Update on fibroblast growth factor 23 in chronic kidney disease. Kidney Int 2012; 82: 737-747.
43. Yilmaz M, Sonmez A, Saglam M et al. Comparison of calcium acetate and sevelamer on vascular function and fibroblast growth factor 23 in CKD patients: A randomized clinical trial. Am J Kidney Dis 2012; 59: 177-185.
44. Ahmed S, O'Neill KD, Hood AF et al. Calciphylaxis is associated with hyperphosphatemia and increased osteopontin expression by vascular smooth muscle cells. Kidney Dis 2001; 37: 1267-1276.
45. Denhardt DT, Guo X. Osteopontin: A protein with diverse functions. FASEB J 1993; 7: 1475-1482.
46. Wada T, McKee MD, Steitz S et al. Calcification of vascular smooth muscle cell cultures. Inhibition by osteopontin. Circ Res 1999; 84: 166-178.
47. Aman K, Tö rnig J, Kugel B et al. Hyperphosphatemia aggravates cardiac fibrosis and microvascular disease in experimental uremia. Kidney Int 2003; 63: 1296-1301.
48. Chue CD, Edwards NC, Moody WE et al. Serum phosphate is associated with left ventricular mass in patients with chronic kidney disease: A cardiac magnetic resonance study. Heart 2012; 98: 219-224.
49. Devereux RB, Wachtell K, Gerdts E et al. Prognostic significance of left ventricular mass change during treatment of hypertension. JAMA 2004; 292: 2350-2356.
50. Mizobuchi M, Finch JL, Slatopolsky E. Differential effects of vitamin D receptor activators on vascular calcification in uremic rats. Kidney Int 2007; 72: 709-715.
51. Mizobuchi M, Morrissey J, Finch JL et al. Combination therapy with an angiotensin-converting enzyme inhibitor and a vitamin D analog suppresses the progression of renal insufficiency in uremic rats. J Am Soc Nephrol 2007; 18: 1796-1806.